Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer
NCT07219303
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to evaluate if adaptive stereotactic body radiation therapy (SBRT) is a safe and effective way to treat prostate cancer in adults. It will assess the safety profile of adaptive SBRT over time. The main questions this trial aims to answer are: What is highest dose of adaptive SBRT without causing serious side effects? Can adaptive SBRT more precisely targeting the prostate while reducing radiation exposure to nearby organs? What side effects do participants experience during treatment, right after treatment, and over the five years post-treatment?
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prostate Cancer (Adenocarcinoma)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Fox Chase Cancer Center
- Last updated on ClinicalTrials.gov
- October 29, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Pennsylvania · 1
- Fox Chase Cancer Center · Philadelphia, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.